MTOR and pancreatic neuroendocrine tumor: Additional therapeutic options include peptide receptor radionuclide therapy and, mainly in patients with pancreatic NET, chemotherapy with alkylating agents such as Streptozotocin (STZ), and treatment with molecular targeted agents such as mammalian target of rapamycin (mTOR) inhibitors and tyrosine kinase inhibitors [13, 26–28].